Zyrtec Becomes PGA Tour's First Allergy Sponsor
In a major health & wellness marketing move, Zyrtec has become the PGA TOUR's first-ever Official Allergy Relief Sponsor. The deal is part of a new 360° campaign aimed at encouraging people with allergies to get outdoors.
The multiyear agreement will see Zyrtec, a Kenvue brand, activate at five tournaments in high-allergen regions with a "Pollen PuttPutt" experience for fans. This move is part of a larger marketing push from Kenvue, which became a fully independent company in August 2023 after being spun off from Johnson & Johnson. Kenvue's CEO, Thibaut Mongon, has indicated the company will continue to increase its advertising investment in 2025, following a 20% budget increase in 2024. The company is shifting its marketing playbook with a strong pivot to social media and influencers to make its brands, including Zyrtec, more visible. This strategy is part of Kenvue's broader effort to drive growth for its portfolio of well-known brands like Tylenol, Neutrogena, and Listerine. The partnership taps into a significant overlap between allergy sufferers and the golf community, as an estimated 85% of PGA Tour players are affected by seasonal allergies. As part of the deal, two-time PGA TOUR champion Akshay Bhatia and rookie Neal Shipley will serve as player ambassadors, appearing in digital and social content. This sponsorship aligns with a rebound in PGA Tour viewership, which saw a 22% increase for its weekend coverage across CBS and NBC during the 2025 season. While the traditional television audience for the PGA Tour has a median age of around 64, its website attracts a predominantly male (74%) audience with strong engagement from visitors under 50. Financially, Zyrtec's parent company Kenvue has been performing well. For the fourth quarter of 2025, Kenvue reported earnings per share of $0.27, beating analysts' expectations. Quarterly revenue also saw a 3.2% year-over-year increase to $3.78 billion, surpassing forecasts.
